Suppr超能文献

术前中性粒细胞与淋巴细胞比值加血小板与淋巴细胞比值可预测肝细胞癌根治性切除术后的预后。

Preoperative Neutrophil-to-Lymphocyte Ratio Plus Platelet-to-Lymphocyte Ratio Predicts the Outcomes after Curative Resection for Hepatocellular Carcinoma.

作者信息

Kabir T, Ye M, Mohd Noor N A, Woon W, Junnarkar S P, Shelat V G

机构信息

Department of General Surgery, Tan Tock Seng Hospital, Singapore.

出版信息

Int J Hepatol. 2019 Apr 2;2019:4239463. doi: 10.1155/2019/4239463. eCollection 2019.

Abstract

BACKGROUND

In recent years, inflammation-based scoring systems have been reported to predict survival in Hepatocellular Carcinoma (HCC). The aim of our study was to validate combined preoperative Neutrophil-to-Lymphocyte ratio (NLR)-Platelet-to-Lymphocyte ratio (PLR) in predicting overall survival (OS) and recurrence free survival (RFS) in patients who underwent curative resection for HCC.

METHODS

We conducted a retrospective study of HCC patients underwent liver resection with curative intent from January 2010 to December 2013. Receiver-operating characteristic (ROC) curve analysis was used to determine the optimal cut-off values for NLR and PLR. Patients with both NLR and PLR elevated were allocated a score of 2; patients showing one or neither of these indices elevated were accorded a score of 1 or 0, respectively.

RESULTS

132 patients with a median age of 66 years (range 18-87) underwent curative resection for HCC. Overall morbidity was 30.3%, 30-day mortality was 2.3%, and 90-day mortality was 6.8%. At a median follow-up of 24 months (range 1-88), 25% patients died, and 40.9% had recurrence. On multivariate analysis, elevated preoperative NLR-PLR was predictive of both OS (HR 2.496; CI 1.156-5.389; =0.020) and RFS (HR 1.917; CI 1.161-3.166; =0.011). The 5-year OS was 76% for NLR-PLR=0 group, 21.7% for the NLR-PLR=1 group, and 61.1% for the NLR-PLR=2 group, respectively. The 5-year RFS was 39.3% for the NLR-PLR=0 group, 18.4% for the NLR-PLR=1 group, and 21.1% for the NLR-PLR=2 group, respectively.

CONCLUSION

The preoperative NLR-PLR is predictive of both OS and RFS in patients with HCC undergoing curative liver resection.

摘要

背景

近年来,有报道称基于炎症的评分系统可预测肝细胞癌(HCC)患者的生存率。本研究的目的是验证术前中性粒细胞与淋巴细胞比值(NLR)和血小板与淋巴细胞比值(PLR)联合应用对接受HCC根治性切除术患者的总生存期(OS)和无复发生存期(RFS)的预测价值。

方法

我们对2010年1月至2013年12月期间接受根治性肝切除术的HCC患者进行了一项回顾性研究。采用受试者工作特征(ROC)曲线分析来确定NLR和PLR的最佳临界值。NLR和PLR均升高的患者得分为2分;仅一项指标升高或两项指标均未升高的患者分别得1分或0分。

结果

132例中位年龄为66岁(范围18 - 87岁)的患者接受了HCC根治性切除术。总体发病率为30.3%,30天死亡率为2.3%,90天死亡率为6.8%。中位随访24个月(范围1 - 88个月)时,25%的患者死亡,40.9%的患者复发。多因素分析显示,术前升高的NLR - PLR可预测OS(HR 2.496;CI 1.156 - 5.389;P = 0.020)和RFS(HR 1.917;CI 1.161 - 3.166;P = 0.011)。NLR - PLR = 0组的5年OS为76%,NLR - PLR = 1组为21.7%,NLR - PLR = 2组为61.1%。NLR - PLR = 0组的5年RFS为39.3%,NLR - PLR = 1组为18.4%,NLR - PLR = 2组为21.1%。

结论

术前NLR - PLR可预测接受根治性肝切除术的HCC患者的OS和RFS。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b47/6466930/0d6ad8f25209/IJH2019-4239463.001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验